"Ovary-sparing hysterectomy raises the risk for accelerated menopause, according to a study published online April 4 in Obstetrics Gynecology.
Removing the ovaries at the time of hysterectomy in women at low risk for ovarian ca"...
Estragyn Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Estragyn (estrone) USP, 0.1% W/W Vaginal Cream is a form of the female hormone estrogen used for short-term treatment of menopausal and postmenopausal symptoms. Common side effects include spotting, changes in vaginal discharge, abdominal pain, nausea or vomiting, breast tenderness, depression, or headaches.
The recommended dose of Estragyn is 2.0 to 4.0 g intravaginally per day, adjusted to the lowest amount that controls symptoms. Estragyn Vaginal Cream is intended for short-term use. Estragyn may interact with grapefruit juice, anticoagulants, insulin and oral diabetes drugs, blood pressure medications, barbiturates, hydantoins, carbamazepine, meprobamates, phenylbutazone, or rifampicin. Tell your doctor all medications and supplements you use. Estragyn is not recommended for use during pregnancy or while breastfeeding.
Our Estragyn (estrone) USP, 0.1% W/W Vaginal Cream Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Estragyn FDA Prescribing Information: Side Effects
Adverse Drug Reaction Overview
Blood and lymphatic system disorders
Increased blood sugar levels; decreased glucose tolerance.
Neuro-ocular lesions (e.g. retinal thrombosis, optic neuritis); visual disturbances; steepening of the corneal curvature; intolerance to contact lenses.
Nausea; vomiting abdominal discomfort (cramps, pressure, pain, bloating).
General disorders and administration site conditions
Fatigue; changes in appetite; changes in body weight; change in libido.
Musculoskeletal and connective tissue disorders
Musculoskeletal pain including leg pain not related to thromboembolic disease (usually transient, lasting 3-6 weeks) may occur.
Nervous system disorders
Aggravation of migraine episodes; headaches; dizziness; neuritis.
Mental depression; nervousness; irritability.
Renal and urinary disorders
Reproductive system and breast disorders
Breakthrough bleeding; spotting; change in menstrual flow; dysmenorrhea; vaginal itching/discharge; dyspareunia; endometrial hyperplasia; pre-menstrual-like syndrome; reactivation of endometriosis; changes in cervical erosion and amount of cervical secretion; breast swelling and tenderness.
Skin and subcutaneous tissue disorders
Isolated cases of: thrombophlebitis; thromboembolic disorders.
Clinical Trial Adverse Drug Reactions
Data are not available.
Less Common Clinical Trial Adverse Drug Reactions
Data are not available.
Post-Market Adverse Drug Reactions
Case #1- Complaint of a burning sensation.
Case# 2- Complaint of inflammation and vaginal discharge.
Read the entire FDA prescribing information for Estragyn (Estrone USP, 0.1% W/W Vaginal Cream)
Additional Estragyn Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.